Advertisement

Corrigendum Free access | 10.1172/JCI96860

A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens

Aaron Y. Chang, Tao Dao, Ron S. Gejman, Casey A. Jarvis, Andrew Scott, Leonid Dubrovsky, Melissa D. Mathias, Tatyana Korontsvit, Victoriya Zakhaleva, Michael Curcio, Ronald C. Hendrickson, Cheng Liu, and David A. Scheinberg

Find articles by Chang, A. in: JCI | PubMed | Google Scholar

Find articles by Dao, T. in: JCI | PubMed | Google Scholar

Find articles by Gejman, R. in: JCI | PubMed | Google Scholar

Find articles by Jarvis, C. in: JCI | PubMed | Google Scholar

Find articles by Scott, A. in: JCI | PubMed | Google Scholar

Find articles by Dubrovsky, L. in: JCI | PubMed | Google Scholar

Find articles by Mathias, M. in: JCI | PubMed | Google Scholar

Find articles by Korontsvit, T. in: JCI | PubMed | Google Scholar

Find articles by Zakhaleva, V. in: JCI | PubMed | Google Scholar

Find articles by Curcio, M. in: JCI | PubMed | Google Scholar

Find articles by Hendrickson, R. in: JCI | PubMed | Google Scholar

Find articles by Liu, C. in: JCI | PubMed | Google Scholar

Find articles by Scheinberg, D. in: JCI | PubMed | Google Scholar

First published September 1, 2017 - More info

Published in Volume 127, Issue 9 (September 1, 2017)
J Clin Invest. 2017;127(9):3557–3557. https://doi.org/10.1172/JCI96860.
Copyright © 2017, American Society for Clinical Investigation

Published September 1, 2017

See the related article at A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

Original citation: J Clin Invest. 2017;127(7):2705–2718. https://doi.org/10.1172/JCI92335

Citation for this corrigendum: J Clin Invest. 2017;127(9):3557. https://doi.org/10.1172/JCI96860

The last two sentences in the first paragraph of the Discussion section were incorrect. The correct sentences are below.

Recently described “ImmTAC” molecules use a TCR-based recognition domain offering similar reactivity to TCRm Abs and demonstrate high affinity (42). Also, TCRm Abs such as Pr20 can target these “undruggable” proteins with high affinity for redirected immune-mediated cytolysis.

The authors regret the error.

Footnotes

See the related article at A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

Version history
  • Version 1 (September 1, 2017): Print issue publication
Advertisement
Advertisement